Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 8

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 8
---
 included in the computation of diluted EPS
as to do so would have been antidilutive:

Schedule of computation of diluted net loss
per share

    March 31, 2025  
    December 31, 2024 
  
    Common stock options 
     10,633,988  
     10,566,488 
  
    Unvested restricted stock 
     -  
     1,626,037 
  
    Warrants 
     1,359,375  
     1,359,375 
  
    Total 
     11,993,363  
     13,551,900 

Stock-Based Compensation

The Company recognizes expense related to the
grant date fair value of stock-based awards in the statements of operations. For stock options issued to employees, non-employees and
members of our board of directors, the Company estimates the grant-date fair value of options using the Black-Scholes option pricing
model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of
the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates, and,
for grants prior to our initial public offering, the value of the common stock. For awards subject to time-based vesting, the Company
recognized stock-based compensation expense, on a straight-line basis over the requisite service period, which is generally the vesting
term of the award.

    11

JUPITER NEUROSCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2025

Note 2 – Significant Accounting Policies,
continued

Clinical Trial Expenses

In preparing financial statements, the Company estimates clinical trial-related expenses based on contracts with
vendors, clinical sites, and consultants. Because payment timing often differs from service delivery, the Company records expenses according
to actual service performance and trial progression, using discussions with internal staff and external providers. Estimates are periodically
adjusted as actual results become known. Accurate accruals depend on timely reporting from third-party vendors, and differences between
estimated and actual expenses, though not expected to be significant, may occur.

Fair Value of Financial Instruments and Fair
Value Measurements

The Company measures its financial assets and
liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts
payable